// App-Quantinova.ai

: Direct Oral Anticoagulant Versus Low Molecular Weight Heparin for the Treatment of Cancer-Associated Thromboembolism: 2021 Updated Meta-Analysis of Randomized Controlled Trials

Researchers

Presenter

  • Corinne Frere

Principal Investigators

  • Dominique Farge

  • Deborah Schrag

  • Pedro H. Prata

  • Jean M. Connors

Medical Centers

  • Institut Universitaire d'Hématologie, EA , Université de Paris, Paris, France

  • Department of Internal Medicine (UF ) : CRMR MATHEC, Maladies Auto-immunes et Thérapie Cellulaire, AP-HP, Saint-Louis Hospital, Paris, France

  • INSERM UMRS-, Sorbonne Université, Paris, France

  • Harvard Medical School, Boston, MA

  • Department of Hematology, AP-HP, Pitié Salpêtrière Hospital, Paris, France

  • Brigham & Women's Hosp./Dana Farber Cancer Inst., Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Hematology and Transplantation, AP-HP, Saint-Louis Hospital, Paris, France

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved